DDInter1055 DDInter1089
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity. Like many other protease inhibitors (e.g. [saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself cannot be cleaved, thus preventing the activity of the HIV-1 protease. Lopinavir was previously under investigation in combination with ritonavir for the treatment of COVID-19 caused by SARS-CoV-2.
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Lopinavir
Levofloxacin {u} (Compound) upregulates {v} (Gene) FKBP14
FKBP14 {u} (Gene) is upregulated by {v} (Compound) Lopinavir
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Saquinavir
Saquinavir {u} (Compound) resembles {v} (Compound) Lopinavir
Levofloxacin {u} (Compound) causes {v} (Side Effect) Renal failure acute
Renal failure acute {u} (Side Effect) is caused by {v} (Compound) Saquinavir
Saquinavir {u} (Compound) resembles {v} (Compound) Lopinavir
Levofloxacin {u} (Compound) upregulates {v} (Gene) FKBP14
FKBP14 {u} (Gene) is upregulated by {v} (Compound) Bisacodyl
Bisacodyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lopinavir
Levofloxacin {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Cimetidine
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lopinavir
Levofloxacin {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lopinavir
Levofloxacin {u} (Compound) causes {v} (Side Effect) Dry eye
Dry eye {u} (Side Effect) is caused by {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lopinavir
Levofloxacin {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lopinavir
Levofloxacin {u} (Compound) causes {v} (Side Effect) Dry eye
Dry eye {u} (Side Effect) is caused by {v} (Compound) Vandetanib
Vandetanib {u} may lead to a major life threatening interaction when taken with {v} Lopinavir
Levofloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lopinavir (Compound)
Levofloxacin (Compound) upregulates FKBP14 (Gene) and FKBP14 (Gene) is upregulated by Lopinavir (Compound)
Levofloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Saquinavir (Compound) and Saquinavir (Compound) resembles Lopinavir (Compound)
Levofloxacin (Compound) causes Renal failure acute (Side Effect) and Renal failure acute (Side Effect) is caused by Saquinavir (Compound) and Saquinavir (Compound) resembles Lopinavir (Compound)
Levofloxacin (Compound) upregulates FKBP14 (Gene) and FKBP14 (Gene) is upregulated by Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir
Levofloxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Cimetidine (Compound) and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Lopinavir
Levofloxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir
Levofloxacin (Compound) causes Dry eye (Side Effect) and Dry eye (Side Effect) is caused by Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir
Levofloxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Oxaliplatin (Compound) and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir
Levofloxacin (Compound) causes Dry eye (Side Effect) and Dry eye (Side Effect) is caused by Vandetanib (Compound) and Vandetanib may lead to a major life threatening interaction when taken with Lopinavir